Volume 29, Issue 3 (Avicenna Journal of Clinical Medicine-Autumn 2022)                   Avicenna J Clin Med 2022, 29(3): 177-183 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbasi M, Mahmoudi K, Amini R. Evaluation of PDL-1 Protein Expression in Tumor Tissues of Patients with Gasteric Cancer. Avicenna J Clin Med 2022; 29 (3) :177-183
URL: http://sjh.umsha.ac.ir/article-1-2499-en.html
1- Department of Internal Medicine, School of Medicine, Hamadan University of Medical Science, Hamadan, Iran
2- Department of Internal Medicine, School of Medicine, Hamadan University of Medical Science, Hamadan, Iran , newmind151@gmail.com
3- Department of Molecular Medicine, School of Medicine, Hamadan University of Medical Science, Hamadan, Iran
Abstract:   (1265 Views)
Background and Objective: Nowadays, it has been proven that the immune system plays a major role in the occurrence or treatment of some cancers. The PDL-1 proteins are among the components of the immune system, which are expressed in different body cells, including B cells and T cells. In this regard, the present study was conducted to determine the frequency of PDL-1 protein expression and its relationship with tumor histopathology in patients with gastric cancer.
Materials and Methods: In this case series study, 100 patients referred to the Oncology Clinic, located in Imam Khomeini Clinic, Hamadan, Iran, between 2016-2021, with the diagnosis of gastric cancer (confirmed by endoscopic biopsy pathology) were selected. Moreover, their PDL-1 protein expression (with IHC) and its relationship with age, gender, metastasis, stage, and grade of the tumor were evaluated.
Results: The average age of patients was 65.53 ± 10.83 years, and 72% were male. The result of PDL-1 protein expression showed that 2 patients were negative, 25 patients were weakly positive and 73 patients were strongly positive. In addition, 69 Out of 100 patients had metastases, 69 cases had high grade and 68 were in stage 4 of the disease. A significant relationship was observed between PDL-1 expression with metastasis, higher grade, and higher stage of the tumor (P<0.05).
Conclusion: Most patients with gastric cancer had a strongly positive expression of PDL-1 protein. Expression of PDL-1 was significantly associated with the severity of gastric cancer (e.g., grade, higher stage, and metastasis); therefore, the PDL-1 biomarker could be used as a determinant of gastric cancer severity and prognosis
Full-Text [PDF 995 kb]   (523 Downloads)    

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb